{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-29",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Buena",
      "state": "NJ",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "89798",
      "recalling_firm": "Teligent Pharma, Inc.",
      "address_1": "105 Lincoln Avenue",
      "address_2": "N/A",
      "postal_code": "08310",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide in the USA and Puerto Rico",
      "recall_number": "D-0693-2022",
      "product_description": "Lidocaine Cream, 4%, packaged in a) Net Wt. 15 grams tubes, NDC 52565-122-15; b) Net Wt. 30 grams tubes, NDC 52565-122-30; c) 5 x 5 gram tubes, NDC 52565-122-07; Manufactured by: Teligent Pharma, Inc. Buena, New Jersey 08310; Manufactured by: Teligent Pharma, Inc., Buena, New Jersey 08310.",
      "product_quantity": "136,960 tubes",
      "reason_for_recall": "cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.",
      "recall_initiation_date": "20220315",
      "center_classification_date": "20220321",
      "termination_date": "20240617",
      "report_date": "20220330",
      "code_info": "Batch: a) 15192, Exp. 2/28/2022; 16278, Exp. 1/31/2023; b) 15124, 15192, Exp. 2/28/2022; 15296, 15336, 15337, 15439, Exp. 3/31/2022; 16278, Exp. 1/31/2023; 16603, 16664, Exp. 3/31/2023;17023, Exp. 6/30/2023; c) 15067, Exp. 2/28/2022; 16664, Exp. 3/31/2023"
    }
  ]
}